Disclosure under SEBI Takeover Regulations

28th September 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Dalal Street Bandra-Kurla Complex, Mumbai 400 001 Bandra (E), Mumbai 400 051 Scrip Code: 500674 Symbol: SANOFI Dear Sir / Madam, Sub.: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”) in respect of inter se transfer of shares exempted under Regulation 10(1)(a)(iii) of the SAST Regulations With reference to the abovementioned subject, Sanofi Healthcare India Private Limited, an entity part of the promoter group of Sanofi India Limited (“Target Company”) has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of the Target Company from Hoechst GmbH, a promoter of the Target Company, on 24th September 2026. This acquisition is an inter-se transfer among members of the promoter and promoter group of the Target Company through a block deal mechanism on the Stock Exchange and falls within the exemption provided under Regulation 10(1)(a)(iii) of the SAST Regulations. The prior intimation under Regulation 10(5) of the SAST Regulations was submitted on 17th September 2026. The aggregate holding of promoter and promoter group before and after the above inter-se transfer remains unchanged. In this regard, please find enclosed herewith the disclosure pursuant to the provision of Regulation 10(6) of the SAST Regulations in the specified format as required to be given for the said acquisition of the equity shares of the Target Company. This is for your information and records. Thanking you. Yours faithfully, For Sanofi Healthcare India Private Limited Neha Pokhrana Company Secretary Membership No.: A40082 Encl.: As above Mr. Haresh Vala Company Secretary and Compliance officer Sanofi India Limited Address: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 DISCLOSURES UNDER REGULATION 10(6) – REPORT TO STOCK EXCHANGES IN RESPECT OF ANY ACQUISITION MADE IN RELIANCE UPON EXEMPTION PROVIDED FOR IN REGULATION 10 OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 1. Name of the Target Company (TC) Sanofi India Limited (“Target Company”) 2. Name of the acquirer(s) Sanofi Healthcare India Private Limited (“Acquirer”) 3. Name of the stock exchange where BSE Limited shares of the TC are listed The National Stock Exchange of India Limited 4. Details of the transaction including The Acquirer has acquired 3,500,000 equity rationale, if any, for the transfer / shares carrying 15.20% of the equity share acquisition of shares. capital of the Target Company from Hoechst GmbH, a promoter of the Target Company, on 24th September 2026. The transaction is being undertaken through the block deal mechanism on the Stock Exchange as an inter-se transfer of shareholding among members of the promoter and promoter group of the Target Company. 5. Relevant regulation under which the The Acquirer is exempted from the requirement acquirer is exempted from making open to make an open offer in terms of Regulation offer. 10(1)(a)(iii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”). Sub-clause (iii) of the SAST Regulations 10(1)(a) states: “a company, its subsidiaries, its holding company, other subsidiaries of such holding company, persons holding not less than fifty per cent of the equity shares of such company, other companies in which such persons hold not less than fifty per cent of the equity shares, and their subsidiaries subject to control over such qualifying persons being exclusively held by the same persons; Explanation: For the purpose of this sub-clause, the company shall include a body corporate, whether Indian or foreign.” 6. Whether disclosure of proposed acquisition - Yes, the disclosure under Regulation 10(5) was required to be made under regulation of the SAST Regulations was required to 10 (5) and if so, be made for the acquisition and was filed - whether disclosure was made and within the timeline specified under the whether it was made within the timeline SAST Regulations. specified under the regulations. - date of filing with the stock exchange. - The disclosure was filed with the Stock Exchanges on 17th September 2026. 7. Details of acquisition Disclosures Whether the required to be disclosures under made under Regulation 10(5) Regulation 10(5) are actually made a. Name of the transferor / seller Hoechst GmbH Yes b. Date of acquisition 24th September 2026 Yes c. Number of shares / voting rights in 3,500,000 Yes respect of the acquisitions from each person mentioned in 7(a) above d. Total shares proposed to be acquired / 15.20% Yes actually acquired as a % of diluted share capital of TC e. Price at which shares are proposed to Rs. 3,052 per share Yes be acquired / actually acquired 8. Shareholding details Pre-Transaction Post-Transaction No. of % w.r.t No. of % w.r.t shares total shares total share held share held capital of TC capital of a Each Acquirer / Transferee and PAC (other than sellers) (*) Sanofi Healthcare India Private Limited Nil Nil 3,500,000 15.20 (Acquirer) PAC: 1. SANOFI 4,865 0.02 4,865 0.02 2. CKW PHARMA EXTRAKT Nil Nil Nil Nil BETEILIGUNGS UND VERWALTUNGS Gm 3. CKW PHARMA EXTRAKT GMBH & Nil Nil Nil Nil Co.KG 4. Future Capital AG Hessen Life Nil Nil Nil Nil Sciences Chemie 5. Sanofi Aventis de Colombia S.A. Nil Nil Nil Nil 6. Sanofi Aventis Deutschland GmbH Nil Nil Nil Nil 7. Starlink Logistics Inc. (SLLI) Nil Nil Nil Nil 8. Aventis Agriculture Nil Nil Nil Nil 9. CARRAIG INSURANCE DAC Nil Nil Nil Nil 10. Sanofi Cathay (Shanghai) Private Nil Nil Nil Nil Equity Investment Fund Partnership (L.P.) 11. Innobio 2 Nil Nil Nil Nil 12. Le Rock Re Nil Nil Nil Nil 13. Limited Liability Company Sanofi Nil Nil Nil Nil Aventis Ukraine 14. Sanofi Aventis del Peru S.A Nil Nil Nil Nil 15. Sanofi Aventis Groupe Nil Nil Nil Nil 16. Sanofi Aventis Korea Co., Ltd. Nil Nil Nil Nil 17. Sanofi Aventis Participations Nil Nil Nil Nil 18. Sanofi Aventis Recherche & Nil Nil Nil Nil Développement 19. Sanofi B.V. Nil Nil Nil Nil 20. Cathay Growth (Quanzhou) Equity Nil Nil Nil Nil Investment Fund L.P 21. Sanofi European Treasury Center Nil Nil Nil Nil 22. Sanofi Foreign Participations B.V. Nil Nil Nil Nil 23. SANOFI GESTION SA Nil Nil Nil Nil 24. SANOFI PASTEUR MERIEUX Nil Nil Nil Nil 25. Sanofi R&D Vaccins Nil Nil Nil Nil 26. Sanofi sp. z.o.o. Nil Nil Nil Nil 27. Sanofi (China) Investment Co. Ltd. Nil Nil Nil Nil TOTAL 4,865 0.02 3,504,865 15.22 b. Each Seller/ Transferor Hoechst GmbH 13,904,722 60.38 10,404,722 45.18 Note: (*) Shareholding of each entity shall be shown separately and then collectively in a group. For Sanofi Healthcare India Private Limited Neha Pokhrana Company Secretary Membership No.: A40082 Date: 28th September 2026 Place: Mumbai